The plant was completed on June 22. Manufacturing readiness was not.
LOTTE Biologics announced on June 22, 2026 that major construction of Songdo Bio Campus Plant 1 was complete and the facility had received approval for use. The company said the physical build included production equipment, piping, electrical systems and control systems—not just the building shell.
The same announcement made clear that another phase followed: commissioning and validation in the second half of the year. In August, LOTTE Biologics consolidated management, manufacturing, quality and engineering teams at Songdo and reiterated targets for GMP readiness in 2026 and commercial operation in 2027. A completed facility and a production-ready GMP system are not the same milestone.
Why validation moves to the foreground after construction
Biopharmaceutical manufacturing is not ready for commercial operation simply because equipment exists. FDA process-validation guidance takes a lifecycle view: after process design comes qualification of facilities, utilities, equipment and the commercial process, followed by continued process verification.
The question therefore changes after physical completion. It becomes less about whether equipment has been installed and more about whether equipment and processes can operate repeatedly under defined conditions—and whether that can be demonstrated through controlled evidence, documents and data.
LOTTE’s job postings show QA, Quality Validation and CSV at the same time
An August 2026 Quality Validation contract posting included preparation and administration of validators and data loggers plus validation-document management. A regular-career posting in the same month described CSV work spanning validation planning and reporting, risk assessment, periodic review, and IQ/OQ/PQ/UAT.
A September QA posting makes the quality layer even more explicit: review of validation and GMP quality documents, checks for record completeness and the posting’s “ALOCA+” / Data Integrity requirements, issue tracking and QA oversight. The hiring language immediately after construction is less about “adding headcount” than about proving the production system.
This is not only a QA story
Validation is not an isolated documentation task owned by one quality team. Earlier Songdo engineering recruitment linked utility operations to commissioning, Field/DCS operation and FAT-to-IOQ validation support, while automation roles combined DCS/PLC systems with validation, CSV and data integrity.
Turning a facility into a GMP manufacturing system therefore connects quality, utilities, automation, IT, QC and technical operations. Physical-equipment knowledge and the ability to qualify, document and control that equipment can sit in the same project.
Where can adjacent-industry experience matter?
Not every biopharma role can be filled from adjacent industries. The current QA posting values GMP, GDP, data-integrity and biopharmaceutical manufacturing experience; CSV hiring also values GMP inspection experience. Regulated product knowledge remains a real boundary.
Engineering can show a different pattern. Earlier Songdo utility hiring considered operating experience from biotech, pharmaceuticals, petrochemicals and industrial plants. Capabilities such as large-system commissioning, DCS/PLC, troubleshooting, qualification documentation and change control can sometimes travel across process industries. The search question is not only “same industry?” but also “same problem, solved with evidence?”
Watch the role mix on the road to GMP readiness
As Plant 1 approaches GMP readiness and commercial operation, the mix of roles can reveal the real transition stage: QA, QC, validation, CSV, utilities, automation and MSAT—and the capabilities repeated across them.
One company’s postings do not prove an industry-wide labor shortage. But the concentration of verification, quality, data and operations work after physical completion is a concrete signal of which capabilities a large biopharma investment needs next.
BANSEOG VIEW
After construction, the next competition is for people who can build a verifiable operating system
Songdo Plant 1 moved from physical completion into commissioning, validation and GMP-readiness work. QA, Quality Validation and CSV roles appearing around the same period are consistent with that transition. Building the plant and proving it can operate for regulated commercial production are different problems.
The hiring boundary should reflect that distinction. Some work requires direct biopharma experience; other capabilities in utilities, automation or IT may be testable in adjacent industries. The next bottleneck may be less “do we have the equipment?” and more “who can prove the equipment, process and data operate consistently under control?”
SOURCES
Primary sources and references
- LOTTE BIOLOGICS — Songdo Bio Campus Plant 1 Construction Completion
June 22, 2026. Physical construction completed; commissioning and validation to follow.
- LOTTE BIOLOGICS — Company-wide move to Songdo
Aug. 18, 2026. Manufacturing, quality and engineering teams consolidated; GMP-ready and commercial-operation targets.
- LOTTE Recruitment — September 2026 QA contract role
Validation/GMP documentation, ALCOA+, Data Integrity, issue tracking and QA oversight.
- LOTTE Recruitment — August 2026 Quality Validation role
Validator/data-logger preparation and validation document management.
- LOTTE Recruitment — August 2026 experienced-hire roles
CSV planning/reporting, risk assessment and IQ/OQ/PQ/UAT.
- LOTTE Recruitment — Earlier Songdo Utility Operations & Automation roles
Historical comparison: commissioning, Field/DCS, FAT-to-IOQ, DCS/PLC, validation, CSV and data integrity.
- FDA — Process Validation: General Principles and Practices
Lifecycle principles for process validation in drug and biologics manufacturing.
- FDA — Data Integrity and Compliance With Drug CGMP
FDA guidance on data integrity under drug CGMP.
Based on public information available as of Sept. 4, 2026: LOTTE Biologics releases, LOTTE public job postings and FDA guidance. Current Aug–Sep 2026 postings are distinguished from earlier Songdo engineering postings. The September QA posting spells the acronym “ALOCA+”; this article focuses on the posting’s stated record-completeness and Data Integrity requirements rather than silently rewriting the source. The presence of specific roles is not treated as a measure of industry-wide labor shortage, and no private Banseog client, candidate or Search evidence is used.